

This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

BUSY WEEK? Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director **Patricia Van Arnum**.

Sponsored By:



Spectrum Offers 1200+ USP/NF cGMP Products.
Order Your 2016 USP Catalog!

[Click Here](#)



1. [Valeant CEO Returns; Provides Business Update](#)

Valeant Pharmaceuticals International's CEO J. Michael Pearson has returned following his recovery from recent health issues as the company prepares to provide a business update. [Read More](#)

2. [Teva Plans New Brand Identity](#)

Teva Pharmaceutical Industries Ltd. announced that it is embarking on a strategic enterprise-wide corporate identity program to build a global brand. The company plans to launch the brand over the next 12 months. [Read More](#)

3. [FDA Accepts Allergan's ANDA for Generic Xifaxan](#)

Allergan plc has received an acceptable for filing letter from the FDA for its abbreviated new drug application to market Rifaximin tablets, 550 mg, a generic version of Valeant Pharmaceuticals' Xifaxan (rifaximin) 550 mg, a drug with US 2015 sales of approximately \$975 million. [Read More](#)

4. [FDA OKs Gilead's HIV Combo Therapy](#)

In an important entry in the antiviral market, the FDA has approved Gilead Sciences' Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Emtricitabine and tenofovir alafenamide are from Gilead Sciences and rilpivirine is from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. [Read More](#)

5. [J&J Opens Life Sciences Incubator in Houston](#)

Johnson & Johnson Innovation LLC has opened JLABS @ TMC, a new 34,000-square-foot life sciences incubator providing entrepreneurs shared lab space, private offices, and modular laboratory suites, as well as equipment and value-added operational, education, and business services. The new JLABS facility can accommodate up to 50 startups and will open with 21 companies. [Read More](#)

6. [EMA Issues Risk Management Module](#)

The European Medicines Agency has published a revision of Module V of the good pharmacovigilance practices on risk management systems for public consultation. GVP modules are a set of guidelines to facilitate and strengthen pharmacovigilance in the European Union. [Read More](#)

7. [Dr. Reddy's Issues Voluntary Recall of Select Lots of Paricalcitol](#)

Dr. Reddy Laboratories has issued a voluntary Class III recall for select lots of paricalcitol capsules due to failed tablet/capsule specifications. The product was recalled due to reports of breakage and leakage of paricalcitol capsules. [Read More](#)

8. [AstraZeneca, Kyowa Hakko Partner](#)

AstraZeneca has entered into an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland, and Liechtenstein. [Read More](#)

9. [EMA Advisory Committee Recommends New Uses for BMS' Cancer Drug](#)

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Bristol-Myers Squibb's Opdivo (nivolumab) for two new indications, adding to the market potential of the company's immuno-oncology drug. [Read More](#)

10. [AstraZeneca, China Medical System Partner for Antihypertensive Drug](#)

AstraZeneca has entered into a licensing agreement with China Medical System Holdings Ltd (CMS) for the commercialization rights in China to its calcium channel blocker, Plendil (felodipine). [Read More](#)

DCAT Week '16 Preview

[Get the Latest News from Senior Executives at DCAT Week '16](#)

What are the major company developments impacting the pharmaceutical manufacturing value chain? DCAT's Member Company Announcement Forum kicks off DCAT Week '16 with the latest news and insight from senior executives. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™_esanders@dcat.org

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org